# Glycine vs Placebo for the Schizophrenia Prodrome

> **NCT00291226** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 8 (actual)

## Conditions studied

- Schizophrenia Prodrome

## Interventions

- **DRUG:** Glycine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00291226
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291226, "Glycine vs Placebo for the Schizophrenia Prodrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00291226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*